Currently, no specific mutation has been identified in IDH-wildtype glioblastomas that could serve as a useful biomarker, in the same way that IDH mutations do for oligodendrogliomas and astrocytomas. Here, IDH1 is linked to astrocytoma (excluding glioblastoma).